Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.

TitleIdentification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.
Publication TypeJournal Article
Year of Publication2015
AuthorsDogruluk, T, Tsang, YHuen, Espitia, M, Chen, F, Chen, T, Chong, Z, Appadurai, V, Dogruluk, A, Eterovic, AKarina, Bonnen, PE, Creighton, CJ, Chen, K, Mills, GB, Scott, KL
JournalCancer Res
Volume75
Issue24
Pagination5341-54
Date Published2015 Dec 15
ISSN1538-7445
KeywordsAnimals, Breast Neoplasms, Cell Line, Tumor, DNA Mutational Analysis, Female, Heterografts, High-Throughput Nucleotide Sequencing, Humans, Immunoblotting, Mice, Mice, Nude, Mutagenesis, Site-Directed, Phenotype, Phosphatidylinositol 3-Kinases, Polymerase Chain Reaction, Transduction, Genetic
Abstract

Large-scale sequencing efforts are uncovering the complexity of cancer genomes, which are composed of causal "driver" mutations that promote tumor progression along with many more pathologically neutral "passenger" events. The majority of mutations, both in known cancer drivers and uncharacterized genes, are generally of low occurrence, highlighting the need to functionally annotate the long tail of infrequent mutations present in heterogeneous cancers. Here we describe a mutation assessment pipeline enabled by high-throughput engineering of molecularly barcoded gene variant expression clones identified by tumor sequencing. We first used this platform to functionally assess tail mutations observed in PIK3CA, which encodes the catalytic subunit alpha of the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) frequently mutated in cancer. Orthogonal screening for PIK3CA variant activity using in vitro and in vivo cell growth and transformation assays differentiated driver from passenger mutations, revealing that PIK3CA variant activity correlates imperfectly with its mutation frequency across breast cancer populations. Although PIK3CA mutations with frequencies above 5% were significantly more oncogenic than wild-type in all assays, mutations occurring at 0.07% to 5.0% included those with and without oncogenic activities that ranged from weak to strong in at least one assay. Proteomic profiling coupled with therapeutic sensitivity assays on PIK3CA variant-expressing cell models revealed variant-specific activation of PI3K signaling as well as other pathways that include the MEK1/2 module of mitogen-activated protein kinase pathway. Our data indicate that cancer treatments will need to increasingly consider the functional relevance of specific mutations in driver genes rather than considering all mutations in drivers as equivalent.

DOI10.1158/0008-5472.CAN-15-1654
Alternate JournalCancer Res.
PubMed ID26627007
PubMed Central IDPMC4681596
Grant ListP30 CA016672 / CA / NCI NIH HHS / United States
U01 CA168394 / CA / NCI NIH HHS / United States
P30CA125123 / CA / NCI NIH HHS / United States
P30 CA125123 / CA / NCI NIH HHS / United States
U01CA168394 / CA / NCI NIH HHS / United States